Related Experiment Video
Updated: Jul 15, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges
Jordi Remon1, Stephanie P L Saw2, Francesco Cortiula3
1Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
Abstract:
Treatment with 3 years of adjuvant osimertinib is considered a new standard in patients with completely resected stage I to IIIA NSCLC harboring a common sensitizing EGFR mutation. This therapeutic approach significantly prolonged the disease-free survival and the overall survival versus placebo and revealed a significant role in preventing the occurrence of brain metastases. However, many unanswered questions remain, including the optimal duration of this therapy, whether all patients benefit from adjuvant osimertinib, and the role of adjuvant chemotherapy in this population. Indeed, there is a renewed interest in neoadjuvant strategies with targeted therapies in resectable NSCLC harboring oncogenic drivers. In light of these considerations, we discuss the past and current treatment options, and the clinical challenges that should be addressed to optimize the treatment outcomes in this patient population.
Insights
Adjuvant osimertinib significantly improves survival for resected EGFR-mutated NSCLC patients. Further research is needed on optimal duration, patient selection, and the role of chemotherapy.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Adjuvant osimertinib is a new standard for resected Stage I-IIIA NSCLC with EGFR mutations.
- It improves disease-free and overall survival, and prevents brain metastases.
Purpose of the Study:
- To review current treatment options for EGFR-mutated NSCLC.
- To discuss unanswered questions and future directions in adjuvant and neoadjuvant therapy.
Main Methods:
- Review of clinical trial data and existing literature.
- Discussion of clinical challenges and future research needs.
Main Results:
- Adjuvant osimertinib demonstrated significant survival benefits compared to placebo.
- Prevention of brain metastases was a key finding.
Conclusions:
- Adjuvant osimertinib is a significant advancement for EGFR-mutated NSCLC.
- Optimal treatment duration, patient stratification, and the role of chemotherapy require further investigation.
- Neoadjuvant targeted therapy is an emerging area for resectable NSCLC.
More Related Videos
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...